entertainment -WSS

entertainment

author：explore 2025-10-01 20:15:22 - browse：2999

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Bird flu in milk supply is likely coming from asymptomatic cows

WSS

HHS secretary Becerra pressed on Change HealthCare cyberattack

FTC falls short on scrutinizing hospital mergers, study says

More tobacco lobbyists active in statehouses

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Health care needs a new profession: neuroimaging counseling

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Wikipedia

entertainment

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

John Green on his newest strategy for fighting tuberculosis

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

In age of alternative facts, a scholarly course on calling out crap

More tobacco lobbyists active in statehouses

Anesthesiologist group: stop taking Ozempic before surgery

Cue Health's Covid

Supreme Court strikes down use of affirmative action

Health care needs a new profession: neuroimaging counseling

focus

Why rehabilitation engineers need to center patients in their research

First U.S. drug developed to treat liver disease MASH is approved

Close Medicare's dangerous gaps in addiction treatment coverage

Cue Health's Covid

John Green on his newest strategy for fighting tuberculosis

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

hotspot

leisure time

focus

Wikipedia